Report Cover

Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Research Report 2021


The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
    1g/20ml
    1.25g/25ml
    2.5g/50ml
    5g/100ml
    10g/200ml

Segment by Application
    Hospital
    Clinic
    Others

By Region
    North America
        U.S.
        Canada
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Asia-Pacific
        China
        Japan
        South Korea
        India
        Australia
        Taiwan
        Indonesia
        Thailand
        Malaysia
        Philippines
        Vietnam
    Latin America
        Mexico
        Brazil
        Argentina
    Middle East & Africa
        Turkey
        Saudi Arabia
        UAE

By Company
    Boya-Bio
    Beijing Tiantan Biological Products
    Hualan Bio
    Guangdong Shuagnlin Bio-pharmacy
    Weiguang Biological
    Sinopharm
    Shanghai RAAS
    CTBB
    Nanyue Biopharming
1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Overview
    1.1 Product Overview and Scope of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
    1.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Type
        1.2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Growth Rate Comparison by Type (2021-2027)
        1.2.2 1g/20ml
        1.2.3 1.25g/25ml
        1.2.4 2.5g/50ml
        1.2.5 5g/100ml
        1.2.6 10g/200ml
    1.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Segment by Application
        1.3.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Comparison by Application: (2021-2027)
        1.3.2 Hospital
        1.3.3 Clinic
        1.3.4 Others
    1.4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Estimates and Forecasts
        1.4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue 2016-2027
        1.4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2016-2027
        1.4.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Region: 2016 Versus 2021 Versus 2027

2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Competition by Manufacturers
    2.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Manufacturers (2016-2021)
    2.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Manufacturers (2016-2021)
    2.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Average Price by Manufacturers (2016-2021)
    2.4 Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Sites, Area Served, Product Type
    2.5 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Competitive Situation and Trends
        2.5.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Concentration Rate
        2.5.2 The Global Top 5 and Top 10 Largest Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Players Market Share by Revenue
        2.5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
    2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Retrospective Market Scenario by Region
    3.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Retrospective Market Scenario in Revenue by Region: 2016-2021
    3.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Retrospective Market Scenario in Sales by Region: 2016-2021
    3.3 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
        3.3.1 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
        3.3.2 North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country
        3.3.3 U.S.
        3.3.4 Canada
    3.4 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
        3.4.1 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
        3.4.2 Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country
        3.4.3 Germany
        3.4.4 France
        3.4.5 U.K.
        3.4.6 Italy
        3.4.7 Russia
    3.5 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Region
        3.5.1 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region
        3.5.2 Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region
        3.5.3 China
        3.5.4 Japan
        3.5.5 South Korea
        3.5.6 India
        3.5.7 Australia
        3.5.8 Taiwan
        3.5.9 Indonesia
        3.5.10 Thailand
        3.5.11 Malaysia
        3.5.12 Philippines
        3.5.13 Vietnam
    3.6 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
        3.6.1 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
        3.6.2 Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country
        3.6.3 Mexico
        3.6.4 Brazil
        3.6.5 Argentina
    3.7 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Facts & Figures by Country
        3.7.1 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country
        3.7.2 Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country
        3.7.3 Turkey
        3.7.4 Saudi Arabia
        3.7.5 UAE
4 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historic Market Analysis by Type
    4.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2016-2021)
    4.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Type (2016-2021)
    4.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Type (2016-2021)

5 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Historic Market Analysis by Application
    5.1 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2016-2021)
    5.2 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Application (2016-2021)
    5.3 Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price by Application (2016-2021)

6 Key Companies Profiled
    6.1 Boya-Bio
        6.1.1 Boya-Bio Corporation Information
        6.1.2 Boya-Bio Description and Business Overview
        6.1.3 Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.1.4 Boya-Bio Product Portfolio
        6.1.5 Boya-Bio Recent Developments/Updates
    6.2 Beijing Tiantan Biological Products
        6.2.1 Beijing Tiantan Biological Products Corporation Information
        6.2.2 Beijing Tiantan Biological Products Description and Business Overview
        6.2.3 Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.2.4 Beijing Tiantan Biological Products Product Portfolio
        6.2.5 Beijing Tiantan Biological Products Recent Developments/Updates
    6.3 Hualan Bio
        6.3.1 Hualan Bio Corporation Information
        6.3.2 Hualan Bio Description and Business Overview
        6.3.3 Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.3.4 Hualan Bio Product Portfolio
        6.3.5 Hualan Bio Recent Developments/Updates
    6.4 Guangdong Shuagnlin Bio-pharmacy
        6.4.1 Guangdong Shuagnlin Bio-pharmacy Corporation Information
        6.4.2 Guangdong Shuagnlin Bio-pharmacy Description and Business Overview
        6.4.3 Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.4.4 Guangdong Shuagnlin Bio-pharmacy Product Portfolio
        6.4.5 Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates
    6.5 Weiguang Biological
        6.5.1 Weiguang Biological Corporation Information
        6.5.2 Weiguang Biological Description and Business Overview
        6.5.3 Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.5.4 Weiguang Biological Product Portfolio
        6.5.5 Weiguang Biological Recent Developments/Updates
    6.6 Sinopharm
        6.6.1 Sinopharm Corporation Information
        6.6.2 Sinopharm Description and Business Overview
        6.6.3 Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.6.4 Sinopharm Product Portfolio
        6.6.5 Sinopharm Recent Developments/Updates
    6.7 Shanghai RAAS
        6.6.1 Shanghai RAAS Corporation Information
        6.6.2 Shanghai RAAS Description and Business Overview
        6.6.3 Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.4.4 Shanghai RAAS Product Portfolio
        6.7.5 Shanghai RAAS Recent Developments/Updates
    6.8 CTBB
        6.8.1 CTBB Corporation Information
        6.8.2 CTBB Description and Business Overview
        6.8.3 CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.8.4 CTBB Product Portfolio
        6.8.5 CTBB Recent Developments/Updates
    6.9 Nanyue Biopharming
        6.9.1 Nanyue Biopharming Corporation Information
        6.9.2 Nanyue Biopharming Description and Business Overview
        6.9.3 Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales, Revenue and Gross Margin (2016-2021)
        6.9.4 Nanyue Biopharming Product Portfolio
        6.9.5 Nanyue Biopharming Recent Developments/Updates

7 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Cost Analysis
    7.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Key Raw Materials Analysis
       7.1.1 Key Raw Materials
       7.1.2 Key Suppliers of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
    7.3 Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19)
    7.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
    8.1 Marketing Channel
    8.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List
    8.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers

9 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Dynamics
    9.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industry Trends
    9.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Growth Drivers
    9.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Challenges
    9.4 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Restraints

10 Global Market Forecast
    10.1 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Estimates and Projections by Type
        10.1.1 Global Forecasted Sales of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type (2022-2027)
        10.1.2 Global Forecasted Revenue of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type (2022-2027)
    10.2 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Estimates and Projections by Application
        10.2.1 Global Forecasted Sales of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application (2022-2027)
        10.2.2 Global Forecasted Revenue of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application (2022-2027)
    10.3 Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Estimates and Projections by Region
        10.3.1 Global Forecasted Sales of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region (2022-2027)
        10.3.2 Global Forecasted Revenue of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
    12.1 Methodology/Research Approach
        12.1.1 Research Programs/Design
        12.1.2 Market Size Estimation
        12.1.3 Market Breakdown and Data Triangulation
    12.2 Data Source
        12.2.1 Secondary Sources
        12.2.2 Primary Sources
    12.3 Author List
    12.4 Disclaimer

List of Tables Table 1. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Covered in This Study Table 5. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Manufacturers (2016-2021) Table 7. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Average Price (US$/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturing Sites and Area Served Table 11. Manufacturers Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Type Table 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2016-2021) & (K Units) Table 16. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2016-2021) Table 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2016-2021) & (K Units) Table 19. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2016-2021) Table 20. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2016-2021) Table 22. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2016-2021) & (K Units) Table 23. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2016-2021) Table 24. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2016-2021) Table 30. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2016-2021) & (K Units) Table 31. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2016-2021) Table 32. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Country (2016-2021) Table 38. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) by Type (2016-2021) Table 39. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Type (2016-2021) Table 40. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) by Type (2016-2021) Table 41. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Type (2016-2021) Table 42. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (US$/Unit) by Type (2016-2021) Table 43. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units) by Application (2016-2021) Table 44. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Application (2016-2021) Table 45. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue (Million US$) by Application (2016-2021) Table 46. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Application (2016-2021) Table 47. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Price (US$/Unit) by Application (2016-2021) Table 48. Boya-Bio Corporation Information Table 49. Boya-Bio Description and Business Overview Table 50. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 51. Boya-Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 52. Boya-Bio Recent Developments/Updates Table 53. Beijing Tiantan Biological Products Corporation Information Table 54. Beijing Tiantan Biological Products Description and Business Overview Table 55. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 56. Beijing Tiantan Biological Products Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 57. Beijing Tiantan Biological Products Recent Developments/Updates Table 58. Hualan Bio Corporation Information Table 59. Hualan Bio Description and Business Overview Table 60. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 61. Hualan Bio Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 62. Hualan Bio Recent Developments/Updates Table 63. Guangdong Shuagnlin Bio-pharmacy Corporation Information Table 64. Guangdong Shuagnlin Bio-pharmacy Description and Business Overview Table 65. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 66. Guangdong Shuagnlin Bio-pharmacy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 67. Guangdong Shuagnlin Bio-pharmacy Recent Developments/Updates Table 68. Weiguang Biological Corporation Information Table 69. Weiguang Biological Description and Business Overview Table 70. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 71. Weiguang Biological Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 72. Weiguang Biological Recent Developments/Updates Table 73. Sinopharm Corporation Information Table 74. Sinopharm Description and Business Overview Table 75. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 76. Sinopharm Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 77. Sinopharm Recent Developments/Updates Table 78. Shanghai RAAS Corporation Information Table 79. Shanghai RAAS Description and Business Overview Table 80. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 81. Shanghai RAAS Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 82. Shanghai RAAS Recent Developments/Updates Table 83. CTBB Corporation Information Table 84. CTBB Description and Business Overview Table 85. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 86. CTBB Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 87. CTBB Recent Developments/Updates Table 88. Nanyue Biopharming Corporation Information Table 89. Nanyue Biopharming Description and Business Overview Table 90. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021) Table 91. Nanyue Biopharming Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Product Table 92. Nanyue Biopharming Recent Developments/Updates Table 93. Production Base and Market Concentration Rate of Raw Material Table 94. Key Suppliers of Raw Materials Table 95. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Distributors List Table 96. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Customers List Table 97. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Trends Table 98. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Growth Drivers Table 99. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Restraints Table 100. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Type (2022-2027) & (K Units) Table 101. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Type (2022-2027) Table 102. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Type (2022-2027) & (US$ Million) Table 103. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Type (2022-2027) Table 104. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Application (2022-2027) & (K Units) Table 105. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Application (2022-2027) Table 106. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Application (2022-2027) & (US$ Million) Table 107. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Application (2022-2027) Table 108. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Forecast by Region (2022-2027) & (K Units) Table 109. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share Forecast by Region (2022-2027) Table 110. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Forecast by Region (2022-2027) & (US$ Million) Table 111. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share Forecast by Region (2022-2027) Table 112. Research Programs/Design for This Report Table 113. Key Data Information from Secondary Sources Table 114. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Figure 2. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Type in 2020 & 2027 Figure 3. 1g/20ml Product Picture Figure 4. 1.25g/25ml Product Picture Figure 5. 2.5g/50ml Product Picture Figure 6. 5g/100ml Product Picture Figure 7. 10g/200ml Product Picture Figure 8. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Application in 2020 & 2027 Figure 9. Hospital Figure 10. Clinic Figure 11. Others Figure 12. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 13. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size 2016-2027 (US$ Million) Figure 14. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales 2016-2027 (K Units) Figure 15. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 16. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Share by Manufacturers in 2020 Figure 17. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Share by Manufacturers in 2020 Figure 18. The Global 5 and 10 Largest Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Players: Market Share by Revenue in 2020 Figure 19. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 20. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region (2016-2021) Figure 21. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Sales Market Share by Region in 2020 Figure 22. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region (2016-2021) Figure 23. Global Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Market Share by Region in 2020 Figure 24. U.S. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Canada Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Germany Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. France Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. U.K. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Italy Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Russia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. China Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. Japan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. South Korea Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. India Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Australia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Taiwan Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Indonesia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Thailand Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Malaysia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Philippines Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Vietnam Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Mexico Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Brazil Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Argentina Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Turkey Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Saudi Arabia Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. UAE Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. Sales Market Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Type (2016-2021) Figure 49. Sales Market Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application (2016-2021) Figure 50. Sales Market Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application in 2020 Figure 51. Revenue Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application (2016-2021) Figure 52. Revenue Share of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) by Application in 2020 Figure 53. Manufacturing Cost Structure of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Figure 54. Manufacturing Process Analysis of Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Figure 55. Human Immunoglobulin(pH4) for Intravenous Injection(COVID-19) Industrial Chain Analysis Figure 56. Channels of Distribution Figure 57. Distributors Profiles Figure 58. Bottom-up and Top-down Approaches for This Report Figure 59. Data Triangulation Figure 60. Key Executives Interviewed

This research study involved the extensive usage of both primary and secondary data sources.  The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. Top-down and bottom-up approaches are used to validate the global market size market and estimate the market size for manufacturers, regions segments, product segments and applications (end users). All possible factors that influence the markets included in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data. The market size for top-level markets and sub-segments is normalized, and the effect of inflation, economic downturns, and regulatory & policy changes or other factors are not accounted for in the market forecast. This data is combined and added with detailed inputs and analysis from QYResearch and presented in this report.
 

After complete market engineering with calculations for market statistics; market size estimations; market forecasting; market breakdown; and data triangulation, extensive primary research was conducted to gather information and verify and validate the critical numbers arrived at. In the complete market engineering process, both top-down and bottom-up approaches were extensively used, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub segments listed in this report. Extensive qualitative and further quantitative analysis is also done from all the numbers arrived at in the complete market engineering process to list key information throughout the report.
 

Secondary Sources occupies Approximately 25% of Sources, such as press releases, annual reports, Non-Profit organizations, industry associations, governmental agencies and customs data, and so on; This research study involved the usage of widespread secondary sources; directories; databases such as Bloomberg Business, Wind Info, Hoovers, Factiva (Dow Jones & Company), TRADING ECONOMICS, and avention; Investing News Network; statista; Federal Reserve Economic Data; annual reports; BIS Statistics; ICIS; company house documents; CAS(American Chemical Society); investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the Light Aircraft market. It was also used to obtain important information about the top players, market classification and segmentation according to industry trends to the bottom-most level, and key developments related to market and technology perspectives.
 

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. The primary sources from the supply side include product manufacturers (and their competitors), opinion leaders, industry experts, research institutions, distributors, dealer and traders, as well as the raw materials suppliers and producers etc.
 

The primary sources from the demand side include industry experts such as business leaders, marketing and sales directors, technology and innovation directors, supply chain executive, end users (product buyers), and related key executives from various key companies and organizations operating in the global market.
 

Primary research was conducted to identify segmentation types, product price range, product applications, key players, raw materials supply and the downstream demand, industry status and outlook, and key market dynamics such as risks, influence factors, opportunities, market barriers, industry trends, and key player strategies.
 

Publisher: QY Research
Chat with us